MedTrace Logo

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00132379 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2014-08-27

No results posted yet for this study

Summary

The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer \[NSCLC\]), can be given to patients with NSCLC without causing unacceptable side effects.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

ABR-217620

10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles

DRUG

docetaxel

75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week

Sponsors & Collaborators

  • Active Biotech AB

    lead INDUSTRY

Principal Investigators

  • Suzanne Kilany · Active Biotech AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States
  • Denmark
  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132379 on ClinicalTrials.gov